— Increases 2021 Revenue Guidance to $117 Million to $121 Million — MENLO PARK, Calif. --(BUSINESS WIRE)--May 10, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for
MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the following upcoming investor conferences: Bank of
Mark L. Alley to serve as Vice President of Sales MENLO PARK, Calif. --(BUSINESS WIRE)--May 4, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L.
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial
Study Initiates with Registration on ClinicalTrials.gov MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 20, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021 .
- Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 5, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 11, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi , M.D., M.Sc . joined the Intersect ENT Board of Directors. Dr.
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West , President & Chief Executive Officer, and Randy Meier , Executive Vice
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 9, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020 .
